155 related articles for article (PubMed ID: 37226096)
41. IgA nephropathy after pembrolizumab therapy for mesothelioma.
Wang R; Das T; Takou A
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257374
[TBL] [Abstract][Full Text] [Related]
42. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
[TBL] [Abstract][Full Text] [Related]
43. Long-Term Response of Pembrolizumab in a Patient with Metastatic Squamous Non-Small Cell Lung Cancer on Hemodialysis: Case Report and Review of the Literature.
Yun JW; Kwon J; Lim T
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837526
[TBL] [Abstract][Full Text] [Related]
44. Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression.
Ishizuka S; Sakata S; Yoshida C; Takaki A; Saeki S; Nakamura K; Fujii K
Respir Investig; 2018 Jul; 56(4):361-364. PubMed ID: 29764752
[TBL] [Abstract][Full Text] [Related]
45. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
[TBL] [Abstract][Full Text] [Related]
46. ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab.
Uner M; Alhasson B; Obhrai J; Bagnasco SM
Virchows Arch; 2021 Apr; 478(4):801-804. PubMed ID: 32691143
[TBL] [Abstract][Full Text] [Related]
47. A Rare Case of C3 Glomerulonephritis Presenting as Pulmonary Renal Syndrome.
Mederos G; Patel H; Hapuarachchi M; Nair R; Ciobanu D; Madhrira M
HCA Healthc J Med; 2020; 1(6):485-488. PubMed ID: 37427045
[TBL] [Abstract][Full Text] [Related]
48. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
Gallan AJ; Alexander E; Reid P; Kutuby F; Chang A; Henriksen KJ
Am J Kidney Dis; 2019 Dec; 74(6):853-856. PubMed ID: 31204194
[TBL] [Abstract][Full Text] [Related]
49. Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma.
Makri OE; Dimitrakopoulos FI; Tsapardoni F; Tsekouras I; Argyriou AA; Kalofonos H; Georgakopoulos CD
Int J Neurosci; 2022 Jul; 132(7):643-648. PubMed ID: 32998608
[TBL] [Abstract][Full Text] [Related]
50. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
[TBL] [Abstract][Full Text] [Related]
51. Likely Recurrence of C3 Glomerulonephritis in Kidney Transplantation: An Entity to Bear in Mind: Case Report.
Perea-Ortega L; León-Fradejas M; Alonso-Titos J; Cabello-Díaz M; Toledo-Rojas R; Sola-Moyano E; Martín-Reyes G; López-Jiménez V; Burgos-Rodríguez D; Hernández-Marrero D
Transplant Proc; 2015 Nov; 47(9):2669-71. PubMed ID: 26680069
[TBL] [Abstract][Full Text] [Related]
52. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
[TBL] [Abstract][Full Text] [Related]
53. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
54. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
Garg N; Zhang Y; Nicholson-Weller A; Khankin EV; Borsa NG; Meyer NC; McDermott S; Stillman IE; Rennke HG; Smith RJ; Pavlakis M
Nephrol Dial Transplant; 2018 Dec; 33(12):2260-2265. PubMed ID: 29370420
[TBL] [Abstract][Full Text] [Related]
55. Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis.
Kawasaki Y; Kanno S; Ono A; Suzuki Y; Ohara S; Sato M; Suyama K; Hashimoto K; Hosoya M
Pediatr Nephrol; 2016 Jul; 31(7):1091-9. PubMed ID: 26846787
[TBL] [Abstract][Full Text] [Related]
56. Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report.
Liu Y; Dong C; He X; Wu P; Shu Y; Chen L
BMC Nephrol; 2023 Mar; 24(1):51. PubMed ID: 36899322
[TBL] [Abstract][Full Text] [Related]
57. Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation.
Naseer MS; Singh A; Singh N
Glomerular Dis; 2022 Apr; 2(2):100-105. PubMed ID: 36751532
[TBL] [Abstract][Full Text] [Related]
58. Myeloma cast nephropathy with diffuse amyloid casts without systemic amyloidosis: two cases report.
Yong ZH; Yu XJ; Lin ZS; Zhou FD; Cen XN; Wang SX; Zhao MH
BMC Nephrol; 2021 Jan; 22(1):6. PubMed ID: 33407225
[TBL] [Abstract][Full Text] [Related]
59. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
[TBL] [Abstract][Full Text] [Related]
60. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
Basnet S; Dhital R; Tharu B
Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
